Get the Daily Brief
Latest Biotech News
FDA approvals and regulatory milestones in oncology
BeOne Medicines won U.S. accelerated approval for sonrotoclax (Beqalzi) in relapsed or refractory mantle cell lymphoma, adding a new BCL-2 competition point against AbbVie and Roche’s Venclexta in...
Cell therapy development and in vivo CAR-T expansion
Create Medicines raised $122 million to advance its in vivo CAR-T programs for cancers and autoimmune diseases, continuing a push toward therapies manufactured inside the body. The financing...
FDA clinical holds and program strategy shifts
Aardvark Therapeutics disclosed it is moving to unblind data from its Phase 3 Prader-Willi syndrome program after the FDA imposed a full clinical hold. The hold follows a cardiac safety signal...
Alzheimer’s disease pipeline: tau-targeting development path
Biogen decided to advance diranersen (BIIB080) into registrational trials for early Alzheimer’s disease despite missing the primary dose-response endpoint in a Phase 2 study. Biogen reported...
Duchenne gene therapy: pivotal milestone toward FDA submission
Regenxbio reported that its Duchenne muscular dystrophy gene therapy RGX-202 met the primary endpoint in a pivotal trial, with the company targeting an FDA submission path in 2027. The update...
Cancer diagnostics: FDA clears solid-tumor genomic profiling
FDA cleared Datar Cancer Genetics’ CellDx-Tissue assay for comprehensive genomic profiling in solid tumors, enabling dual DNA and RNA analysis from formalin-fixed paraffin-embedded samples. The...
Antibiotic resistance and AI-driven optimization
Researchers at the University of Pennsylvania introduced ApexGO, an AI-powered method for peptide antibiotic optimization that starts with imperfect candidate peptides and iteratively improves...
Gene therapy safety: immune suppression may blunt efficacy
A study from Encoded Therapeutics reported that a gene-therapy safety strategy used to mitigate immune responses—steroids and sirolimus—may reduce the effectiveness of the delivered therapy. The...
Gene therapy & immune engineering momentum
Regenxbio said its Duchenne muscular dystrophy gene therapy RGX-202 cleared a key bar in a pivotal study, setting up an FDA submission process aimed at commercializing a new option for a market...
Cell therapy financing & scale-up
Create Medicines raised $122 million to advance in vivo CAR-T programs spanning autoimmune disease and oncology, betting on one-day manufacturing inside the patient rather than traditional ex vivo...
Diagnostics regulatory & reimbursement wins
The FDA cleared Datar Cancer Genetics’ CellDx-Tissue assay, a dual DNA/RNA comprehensive genomic profiling test designed for solid tumors using formalin-fixed, paraffin-embedded tissue. The test...
Oncology pipeline signals: new data & trial direction
Biogen advanced diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease despite missing a key phase II primary endpoint, signaling that tau-pathology and biomarker effects...
Antibiotics innovation using AI and host pathways
A University of Queensland-led effort reported a precision strategy against drug-resistant bacteria that activates immune-cell mitochondrial fission, leveraging innate mechanisms rather than...
Hospital automation funding for infection control
Shyld AI raised $13.4 million to expand its AI-powered UV disinfection platform that autonomously sanitizes hospital rooms. The company positioned the technology as a way to reduce...
Proton therapy expansion across Europe
Plans announced for five new proton therapy centers across Romania, Greece, Italy, Northern Ireland, and Poland aim to expand treatment capacity for patients across Europe. The initiative builds...
Major strategic deal-making in oncology
Bristol Myers Squibb and Hengrui Pharma signed a collaboration covering 13 early-stage programs in oncology, hematology, and immunology that could reach more than $15 billion in total value. Under...
FDA and regulatory environment: leadership shift after Makary exit
FDA leadership is in flux after Marty Makary’s resignation, with Kyle Diamantas stepping in as acting commissioner. Multiple reports emphasized that the leadership transition is raising...
EV and microbiome-adjacent biologics innovation
Researchers reported that serum extracellular vesicle N-glycomes can classify childhood epilepsy using a non-invasive biomarker approach. The work, published in Engineering, leverages N-glycan...
Gene therapy in Duchenne pushes toward an FDA submission
Regenxbio reported that its Duchenne muscular dystrophy gene therapy RGX-202 met a pivotal clinical bar, setting the stage for an FDA submission and accelerating the company’s path toward...
Car-T manufacturing and delivery scale-up via funding and automation
Create Medicines raised $122 million to expand its in vivo CAR-T platform, focusing on faster, one-day manufacturing using an mRNA-lipid nanoparticle approach to reprogram T cells, NK cells and...